Wall Street analysts expect Selecta Biosciences Inc (NASDAQ:SELB) to post earnings per share of ($0.79) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Selecta Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.87) and the highest estimate coming in at ($0.70). Selecta Biosciences posted earnings of ($0.66) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 19.7%. The company is scheduled to announce its next earnings report on Tuesday, November 6th.
According to Zacks, analysts expect that Selecta Biosciences will report full year earnings of ($3.07) per share for the current year, with EPS estimates ranging from ($3.13) to ($3.00). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.92) per share, with EPS estimates ranging from ($3.01) to ($2.82). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Selecta Biosciences.
Selecta Biosciences (NASDAQ:SELB) last released its earnings results on Wednesday, August 8th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16).
Several analysts recently weighed in on the company. BidaskClub downgraded Selecta Biosciences from a “buy” rating to a “hold” rating in a research report on Friday, October 5th. Stifel Nicolaus assumed coverage on Selecta Biosciences in a research report on Friday, September 14th. They set a “buy” rating and a $24.00 price objective for the company. Canaccord Genuity restated a “buy” rating and set a $40.00 price objective on shares of Selecta Biosciences in a research report on Wednesday, July 11th. Zacks Investment Research downgraded Selecta Biosciences from a “hold” rating to a “sell” rating in a research report on Wednesday, August 29th. Finally, Mizuho restated a “buy” rating and set a $30.00 price objective on shares of Selecta Biosciences in a research report on Thursday, August 9th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $27.40.
Hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers lifted its position in shares of Selecta Biosciences by 43.7% during the 2nd quarter. Rhumbline Advisers now owns 16,792 shares of the company’s stock worth $222,000 after buying an additional 5,103 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Selecta Biosciences by 37.0% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 33,700 shares of the company’s stock worth $447,000 after buying an additional 9,100 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Selecta Biosciences by 27.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 47,273 shares of the company’s stock worth $626,000 after purchasing an additional 10,114 shares in the last quarter. A.R.T. Advisors LLC increased its holdings in Selecta Biosciences by 225.5% in the 1st quarter. A.R.T. Advisors LLC now owns 59,584 shares of the company’s stock worth $607,000 after purchasing an additional 41,277 shares in the last quarter. Finally, Proxima Capital Management LLC acquired a new position in Selecta Biosciences in the 2nd quarter worth about $1,075,000. Institutional investors and hedge funds own 48.74% of the company’s stock.
Shares of NASDAQ:SELB traded up $1.05 during trading on Friday, reaching $14.23. 196,196 shares of the company traded hands, compared to its average volume of 217,394. The company has a debt-to-equity ratio of 0.87, a quick ratio of 4.96 and a current ratio of 4.96. Selecta Biosciences has a 52 week low of $7.95 and a 52 week high of $24.02. The company has a market cap of $348.26 million, a price-to-earnings ratio of -4.45 and a beta of -3.47.
About Selecta Biosciences
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Read More: Do You Need a Fiduciary?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.